Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Acquisitions - Additional Information (Detail)

v3.2.0.727

Acquisitions - Additional Information (Detail) - USD ($) shares in Millions		12 Months Ended
	Jan. 17, 2012	Dec. 31, 2013
Onco Hist [Member]
Business Acquisition [Line Items]
Fair value of intangible asset		$ 10,559,820
Symbio Tec Gmbh [Member]
Business Acquisition [Line Items]
Shares of common stock exchanged in acquisition	25.6
Business acquisitions full consideration transferred	$ 9,750,000
Business acquisition, Assumption of note payable	$ 411,000
Business acquisition, Stock issuance costs	80774
Business acquisition, Description		SymbioTec is principally focused on the discovery of therapies designed to treat cancer in humans. SymbioTec's lead product candidate, OncoHist, is in the pre-clinical stage of development for the treatment of refractory AML and Non-Hodgkins Lymphoma. OncoHist has been granted orphan drug status by both the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency.
Forecasting period for revenue and operating projections		18 years
Discount rate used to estimate fair value of intangible asset		50.00%
Estimated cost to complete pre-clinical work for IND filing		$ 10,000,000
Symbio Tec Gmbh [Member] \| Onco Hist [Member]
Business Acquisition [Line Items]
Fair value of intangible asset	$ 9,580,000

- Definition

With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents disclosure of the line item or line items in the financial statements in which the amount of any issuance related costs which have not been expensed are recognized including, as appropriate, the accounting treatment applied.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensedFinancialStatementCaption
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Discount rate used to estimate the fair value of servicing assets and servicing liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 50

-Section 50

-Paragraph 2

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=56950315&loc=d3e122596-111746

+ Details

Name:	us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Business Combination Purchase Consideration Notes Payable

+ References

No definition available.

+ Details

Name:	xbio_BusinessCombinationPurchaseConsiderationNotesPayable
Namespace Prefix:	xbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Estimated Cost To Complete Pre-Clinical Work For Investigation New Drug Filing

+ References

No definition available.

+ Details

Name:	xbio_EstimatedCostToCompletePreClinicalWorkForInvestigationNewDrugFiling
Namespace Prefix:	xbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Exchange Of Common Stock Shares Shares

+ References

No definition available.

+ Details

Name:	xbio_ExchangeOfCommonStockSharesShares
Namespace Prefix:	xbio_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Forecasting Period

+ References

No definition available.

+ Details

Name:	xbio_ForecastingPeriod
Namespace Prefix:	xbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=xbio_OncoHistMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=xbio_SymbioTecGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: